Animal Blood Plasma and Derivatives Market Size, Share & Trends Analysis Report By Derivative Type (Immunoglobulin, Fibrinogen, Serum Albumin, Fetal Bovine Serum, Thrombin, Others), By Animal Type (Bovine, Porcine, Ovine, Poultry, Others), By Application (Animal Feed, Pharmaceuticals, Food & Beverages, Pet Food, Diagnostics & Research, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026–2034

Animal Blood Plasma and Derivatives Market Size

The global Animal Blood Plasma and Derivatives Market is valued at USD 1,095.00 Million in 2025 and USD 1,148.56 Million in 2026. The market is projected to reach USD 1655.52 Million by 2034, registering a 4.70% CAGR during the forecast period.

The animal blood plasma and derivatives market covers the collection, separation, purification and commercialization of blood-derived materials obtained from livestock and other animals. Important products include plasma proteins, immunoglobulins, fibrinogen, serum albumin, fetal bovine serum, thrombin, newborn calf serum and other specialized biological fractions. These materials serve a diverse customer base spanning animal nutrition, pet food, food processing, pharmaceuticals, diagnostics, biotechnology, research and cell culture. Merck's current fetal bovine serum portfolio, for example, includes sterile-filtered products sourced from multiple geographic origins for mammalian cell culture, while its specialized products are differentiated through filtration, irradiation, endotoxin and viral testing.

Animal blood is also an important animal-by-product stream within the circular bioeconomy. The European Commission identifies blood as an animal by-product generated during slaughter and notes that these materials can contain substantial nutritional and energetic value while requiring appropriate processing to prevent disease transmission. The EU framework specifically regulates blood and blood products used in animal feed and other applications.

Animal Blood Plasma and Derivatives Market Drivers

Functional plasma proteins are gaining importance in animal nutrition

Spray-dried plasma is increasingly used as a functional animal-nutrition ingredient rather than simply as a conventional protein source. APC's product portfolio covers plasma applications across swine, poultry, ruminants, aquaculture and companion animals, reflecting the broadening role of plasma proteins in commercial feed formulations.

The largest opportunity is associated with young-animal diets, where feed intake, gut integrity and immune status can influence subsequent growth performance. APC's June 2026 research reported improved nursery-pig growth when plasma supplementation was extended beyond the initial two weeks after weaning, while another June 2026 publication evaluated plasma inclusion in diets containing wheat and barley.

This gives plasma a differentiated commercial position because feed manufacturers can use the ingredient for nutritional and functional purposes simultaneously. The demand mechanism therefore extends beyond protein replacement toward improving feed performance, digestibility and animal resilience.

Pet-food manufacturers are expanding the use of functional animal proteins

The pet-food industry is increasingly using animal-origin ingredients for protein quality, palatability, texture, moisture management and functional nutrition. Sonac's animal-protein platform spans pet food and feed applications, while APC has published research and product information around plasma use in canine nutrition.

The role of plasma is broader than simple protein fortification. Functional proteins can support formulation goals involving water retention, emulsification, palatability and nutritional performance, giving processors an opportunity to position plasma-derived ingredients as specialized formulation components.

The growth of premium pet food also creates opportunities for differentiated animal-origin ingredients with documented composition, traceability and application performance. This favors producers that can supply standardized plasma products rather than commodity blood meal alone.

Slaughter by-product valorization is strengthening the economics of blood processing

Animal blood is generated in large volumes during slaughter and can be recovered into plasma, hemoglobin, red-cell products and other fractions instead of being treated primarily as a disposal stream. The European Commission recognizes blood as an animal by-product and emphasizes the need to recover its nutritional and energetic value while maintaining appropriate health controls.

This creates a strong economic incentive for vertically integrated processors. A single raw-material stream can supply several differentiated products serving feed, pet food, food, pharmaceutical and technical applications. The value of blood therefore increases when processors can separate fractions and match each output with a higher-value end market.

SARIA's business model is built around converting animal-origin materials into ingredients for food, animal feed, aquaculture, pet food, pharmaceutical and energy applications, demonstrating how animal by-product recovery is increasingly treated as a multi-market resource platform.

Animal Blood Plasma and Derivatives Market Restraints

Biosafety and animal-by-product regulation increase processing complexity

Blood-derived ingredients require stringent control because untreated animal material can carry pathogens. EU regulations require blood products intended for animal feed to meet specified processing and microbiological requirements. For certain imported porcine blood products, EU rules require heat treatment and defined storage conditions before use in feed.

These controls increase costs through validated processing, microbiological testing, traceability, approved facilities, storage requirements and certification. International suppliers must also manage different import and animal-health requirements across destination markets.

Raw-material quality and supply are closely tied to livestock and slaughter activity

The supply of animal blood depends on livestock populations, slaughter volumes, processing locations and animal-health conditions. Regional disruptions in livestock production or restrictions on animal movement can influence the availability and quality of raw material.

For high-purity serum products, quality requirements become even more demanding. Current FBS specifications can include defined country of origin, sterile filtration, testing for viruses and mycoplasma, endotoxin limits and additional irradiation or processing requirements.

This creates a higher barrier to entry for manufacturers targeting pharmaceutical, diagnostics and biotechnology customers because reliable supply alone is insufficient without consistent qualification and documentation.

Animal Blood Plasma and Derivatives Market Opportunities

Higher-value plasma fractions and application-specific ingredients

The market is moving toward greater specialization in plasma-derived products. APC's portfolio includes different plasma formats and blood-derived proteins, while recent research continues to evaluate applications in swine, poultry, aquaculture and companion animals.

Manufacturers can increase value by tailoring products around species, animal age, feed format, processing requirements or targeted functional properties. Granulated and specialized plasma products can also improve handling, blending and dosing compared with conventional powders.

Life-science and biomanufacturing applications

Animal serum and purified plasma proteins continue to serve cell culture, research and biotechnology applications. Merck's current FBS portfolio includes products for mammalian cell culture and specialized laboratory use, with different grades and processing specifications.

The opportunity is particularly relevant for products with controlled origin, high purity, validated filtration, irradiation and documentation. Customers in pharmaceutical and bioprocessing environments place greater emphasis on lot consistency and traceability, supporting higher-value product categories than commodity feed ingredients.

Derivative Type Segment Analysis

Immunoglobulin remains the largest derivative segment

The Immunoglobulin segment accounts for 33% of the 2026 market, equivalent to USD 379.02 Million, and is projected to reach 34% by 2034, equivalent to USD 531.76 Million. The segment is projected to register a 4.32% CAGR.

Immunoglobulins are important components of plasma because of their biological and functional properties. In animal nutrition, plasma-derived immunoglobulins contribute to the functional value of spray-dried plasma, while in research and biological applications they form part of specialized plasma and serum products.

Fibrinogen is expanding across specialized biological applications

The Fibrinogen segment represents 15% of the 2026 market, equivalent to USD 172.28 Million, and reaches 17% by 2034, equivalent to USD 265.88 Million. The segment is projected to grow at a 5.57% CAGR.

Fibrinogen is a plasma protein associated with coagulation and fibrin formation and is used in specialized biological, diagnostic and research applications. Its commercial value is strongly influenced by purity, consistency and processing quality.

Serum Albumin maintains demand from biotechnology and research

The Serum Albumin segment accounts for 25% of the 2026 market, representing USD 287.14 Million, and reaches 25% by 2034, representing USD 391.00 Million. The segment is projected to grow at a 3.93% CAGR.

Serum albumin is used across life-science applications as a protein component and stabilizing material. The continued presence of bovine-derived albumin and serum products across major life-science portfolios supports demand for purified animal proteins.

Application Analysis

Animal Feed represents the largest application

The Animal Feed segment accounts for 35% of the 2026 market, equivalent to USD 402.00 Million, and reaches 34% by 2034, equivalent to USD 531.76 Million. The segment is projected to grow at a 3.56% CAGR.

Animal feed is the largest application because spray-dried plasma is used as both a protein ingredient and a functional component in livestock, poultry and aquaculture diets. APC's product portfolio covers plasma applications across multiple animal species, while current scientific work continues to evaluate plasma's effects on performance, digestibility and health.

Pharmaceuticals support demand for higher-purity blood derivatives

The Pharmaceuticals segment represents 25% of the 2026 market, equivalent to USD 287.14 Million, and reaches 27% by 2034, equivalent to USD 422.28 Million. The segment is projected to grow at a 4.94% CAGR.

Pharmaceutical and biotechnology customers require animal-derived proteins and serum products with consistent specifications, traceability and controlled processing. Current Merck products demonstrate how FBS is differentiated by origin, filtration, irradiation and testing, while specialized animal proteins are supplied for biological and pharmaceutical applications.

Food & Beverages use plasma proteins for functional properties

The Food & Beverages segment accounts for 15% of the 2026 market, equivalent to USD 172.28 Million, and remains at 15% in 2034, equivalent to USD 234.60 Million. The segment is projected to grow at a 3.93% CAGR.

Animal plasma proteins can provide functional characteristics such as emulsification, water retention, binding and texture modification in food formulations. The application requires controlled processing and quality consistency, creating demand for specialized rather than commodity blood-derived ingredients.

Animal Blood Plasma and Derivatives Market Regional Analysis

North America Animal Blood Plasma and Derivatives Market

The North America market represents 32% of the 2026 global market, equivalent to USD 367.54 Million, and reaches 30% by 2034, equivalent to USD 469.20 Million. The regional market is projected to grow at a 3.10% CAGR.

North America represents the largest regional market due to its large livestock-processing base, established animal-feed industry, developed rendering infrastructure and substantial biotechnology and life-science ecosystem. Large processors and serum suppliers maintain production and commercial operations across the region.

Europe Animal Blood Plasma and Derivatives Market

The Europe market accounts for 24% of the 2026 market, equivalent to USD 275.65 Million, and reaches 23% by 2034, equivalent to USD 359.72 Million. The market is projected to grow at a 3.38% CAGR.

Europe has a mature animal-by-product processing industry and a comprehensive regulatory framework governing blood and other animal-derived materials. The European Commission identifies blood as an animal by-product and maintains specific rules covering approved establishments, processing and end uses.

APAC

The APAC market represents 28% of the 2026 market, equivalent to USD 321.60 Million, and increases to 31% by 2034, equivalent to USD 484.84 Million. The region is projected to grow at a 5.27% CAGR.

APAC is the fastest-growing regional market as livestock production, poultry, aquaculture, pet food and biotechnology activity expand across the region. The growing commercialization of animal-derived proteins and increasing interest in functional feed ingredients are supporting the regional opportunity.

Middle East and Africa Animal Blood Plasma and Derivatives Market

The Middle East and Africa market represents 8% of the 2026 market, equivalent to USD 91.88 Million, and reaches 8% in 2034, equivalent to USD 125.12 Million. The regional market is projected to grow at a 3.93% CAGR.

The Middle East and Africa market is supported by increasing livestock and poultry production, feed-industry modernization and rising demand for standardized functional animal ingredients. Suppliers with reliable international logistics and validated processing systems are positioned to serve markets where local blood fractionation infrastructure is less developed.

LATAM Animal Blood Plasma and Derivatives Market

The LATAM market represents 8% of the 2026 market, equivalent to USD 91.88 Million, and reaches 8% in 2034, equivalent to USD 125.12 Million. The region is projected to grow at a 3.93% CAGR.

Latin America has strong livestock, poultry, pork and aquaculture production and therefore provides substantial raw-material availability for animal-protein processing. Regional processors can convert slaughter by-products into feed, pet-food and specialty protein ingredients, creating additional value within the agricultural supply chain.

Competitive Landscape

Competition in the animal blood plasma and derivatives market is driven by raw-material access, processing scale, fractionation technology, biosafety systems, quality control, regulatory compliance and downstream application expertise.

APC is a specialist functional-protein producer with a portfolio centered on spray-dried plasma and red-cell products. Its applications span swine, poultry, ruminants, aquaculture and companion animals. APC also continues to invest in scientific research covering plasma supplementation, digestibility, gut health and animal performance.

Darling Ingredients and Sonac operate a vertically integrated animal-by-product platform. Darling processes animal-agriculture by-products across a large international network, while Sonac's activities include blood processing and the production of plasma and other animal-derived ingredients for feed and pet-food applications.

Key Market Players

• Darling Ingredients / Sonac
• APC
• SARIA Group
• VEOS Group
• Lican Food
• Bovogen Biologicals
• Merck KGaA / Sigma-Aldrich
• Thermo Fisher Scientific
• Proliant
• Kraeber & Co.
• Rocky Mountain Biologicals
• Lake Immunogenics
• LAMPIRE Biological Laboratories
• ANZCO Foods Healthcare
• Essentia Protein Solutions

Recent Developments

September 2026 – SARIA agreed to acquire a 36.45% stake in Chilean fish by-product processor Fiordo Austral. The transaction expands SARIA's presence in Latin America and the marine-ingredients sector while combining Fiordo Austral's salmon by-product processing capabilities with SARIA's technical and commercial network. The deal strengthens SARIA's broader animal-by-product valorization platform and expands its access to specialized aquaculture and animal-nutrition ingredients. Source: SARIA official press release, September 2026.

June 2026 – APC released research on extending plasma supplementation in nursery pig diets. The company reported that continued plasma supplementation beyond the first two weeks following weaning improved nursery-pig growth outcomes and increased final nursery body weight in the study. The research supports broader use of functional plasma products across the nursery feeding cycle. Source: APC official announcement, June 2026.